While reporting first-quarter results on Tuesday, Johnson & Johnson (JNJ) said, given global supply surplus and demand uncertainty, it is suspending COVID-19 Vaccine sales guidance. The company maintained 2022 full-year guidance for adjusted operational earnings per share and base business operational sales.
from RTT - Earnings https://ift.tt/JIMHmC9
via IFTTT
No comments:
Post a Comment